-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $40

Benzinga·12/17/2025 12:26:43
Listen to the news
Truist Securities analyst Asthika Goonewardene initiates coverage on Zymeworks (NASDAQ:ZYME) with a Buy rating and announces Price Target of $40.